HR 5247
115th Congress
House
Health
Business records
Civil actions and liability
Drug safety, medical device, and laboratory regulation
Drug therapy
Government information and archives
Long-term, rehabilitative, and terminal care
Medical research
Prescription drugs
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Introduced: March 13, 2018
Introduced by:
Fitzpatrick, Brian K.
Republican
· Pennsylvania
See on congress.gov
Everywhere this bill has been
28 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 9, 2018
Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.
Mar 23, 2018
Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
Mar 22, 2018
Received in the Senate.
Mar 21, 2018
Motion to reconsider laid on the table Agreed to without objection.
Mar 21, 2018
On passage Passed by recorded vote: 267 - 149 (Roll no. 121). (text: CR H1738-1739)
Mar 21, 2018
Passed/agreed to in House: On passage Passed by recorded vote: 267 - 149 (Roll no. 121).(text: CR H1738-1739)
Mar 21, 2018
On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).
Mar 21, 2018
Considered as unfinished business. (consideration: CR H1748-1750)
Mar 21, 2018
POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.
Mar 21, 2018
The previous question on the motion to recommit with instructions was ordered without objection.
Mar 21, 2018
DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.
Mar 21, 2018
Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1746-1747)
Mar 21, 2018
The previous question was ordered pursuant to the rule.
Mar 21, 2018
DEBATE - The House proceeded with one hour of debate on H.R. 5247.
Mar 21, 2018
The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
Mar 21, 2018
Considered under the provisions of rule H. Res. 787. (consideration: CR H1738-1748)
Mar 20, 2018
Rule H. Res. 787 passed House.
Mar 19, 2018
Rules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
Mar 16, 2018
Referred to the Subcommittee on Health.
Mar 13, 2018
On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
Mar 13, 2018
Failed of passage/not agreed to in House: On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
Mar 13, 2018
Considered as unfinished business. (consideration: CR H1528-1529)
Mar 13, 2018
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Mar 13, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5247.
Mar 13, 2018
Considered under suspension of the rules. (consideration: CR H1521-1527; text of measure as introduced: CR H1521-1522)
Mar 13, 2018
Mr. Walden moved to suspend the rules and pass the bill.
Mar 13, 2018
Referred to the House Committee on Energy and Commerce.
Mar 13, 2018
Introduced in House
Votes taken on this bill
3
| Date | Chamber | What was voted on | Result | Yes–No | |
|---|---|---|---|---|---|
| Mar 22, 2018 | House · vote #121 | On Passage | Passed | 267–149 | See who voted → |
| Mar 22, 2018 | House · vote #120 | On Motion to Recommit with Instructions | Failed | 182–233 | See who voted → |
| Mar 13, 2018 | House · vote #102 | On Motion to Suspend the Rules and Pass | Failed | 259–140 | See who voted → |
Plain-English summary
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must publish annual summaries on any use of the drug in accordance with these provisions.
The bill limits the liability of a sponsor, manufacturer, licensed physician, clinical investigator, or hospital that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.
What's happening now
Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.
Committees of jurisdiction
2